Omega-3 Specialty Lipids: Fish Oil EPA, DHA and Algal Ingredient Sourcing

Industry Overview

Omega-3 specialty lipids are becoming vital nutrient ingredients that are employed in the manufacture of dietary supplements, infant formula, pharmaceuticals, functional foods, beverages, and animal nutrition products. Fish oil continues to be one of the main sources of EPA and DHA, whereas interest in microalgae-derived ingredients is increasing as producers look for traceable and scalable alternatives to marine oil products. On the product development front, in April 2026, dsm-firmenich launched Veramaris O3 Max Pure, which is a microalgal oil designed to contain the same EPA-to-DHA ratio as premium fish oil. This shows the efforts of producers to improve the suitability of algae-derived lipids for traditional nutritional applications.

Increasing Demand for Fish Oil-Derived EPA

The EPA extracted from fish oil is extensively used in cardiovascular health supplements, clinical nutrition, and nutritional ingredients. Suppliers are offering high purity, concentration, stability, and sensory-neutral fish oils that can cater to the needs of the food manufacturers. In March 2025, the omega-3 products division of Natac named Innovaoleo introduced Omega 3 Star fish oil that consists of 18% of EPA and 12% of DHA fish oil. The product was designed for applications in food, nutraceuticals, and pet nutrition products and was produced in the company's plant in As Somozas, Spain. The fish oil was engineered to offer high purity and stability along with neutral taste, odor, and appearance.

Growing Applications of Fish Oil-Derived DHA

Fish oil-based DHA continues to be crucial for infant formulas, maternal supplementation, cognitive support formulas, and specialized dietary supplements. Companies are currently developing liquid, concentrated formulations that allow consumers to take a meaningful amount of DHA and EPA without having to rely entirely on capsules. For example, in January 2026, OCuSOFT, introduced the product called Retaine Omega Forté. It is a liquid omega-3 supplement with 2,490 mg of EPA and DHA together with another 405 mg of omega-3 fatty acids. The formulation uses anchovy oil sourced from the South Pacific and natural triglyceride-form omega-3s, with lemon flavoring to improve sensory acceptance. Despite being marketed as a ready-to-use supplement rather than pure DHA, this new product release is an example of fish oil delivery format innovations.

Expansion of Algal DHA Ingredients

The market observes an increasing trend towards the use of Algal DHA in commercial settings since manufacturers are currently looking for sources of fish-free ingredients in their formulations of dietary supplements, maternal nutrition, and functional food. Controlled fermentation provides better control of the production process and the formulation of the ingredient without having to depend directly on wild-caught fish. In January 2026, Aker BioMarine revealed plans of launching Revervia, a high concentrate of DHA from algae for the Indian market. This ingredient comes from natural fermentation and can be used in capsules, powders, and other functional foods.

Emerging Commercial Potential of Algal EPA

The use of algal EPA is gaining prominence as companies try to increase the availability of non-fish omega-3 sources beyond DHA-focused applications. Historically, manufacturing algae with high levels of EPA has presented several challenges, prompting research into better strains and processes. Innovations in this context led to the April 2026 introduction of Fermentalg’s OMEGA ΩRIGINS, which is a collection of algal EPA/DHA oils made from Fermentalg's patent-pending fermentation technology and its own proprietary Schizochytrium strain. The company’s flagship 400/200 formula features 40% EPA and 20% DHA. These concentrations are attained without the need for an additional step of oil concentration.

Innovation in Concentrated Omega-3 Oils

The use of concentrated omega-3 oils is gaining importance among supplement companies, who are attempting to increase the level of active fatty acids, reduce dosage, and improve formula versatility. Companies are also combining different sources of marine lipids to differentiate their nutritional profile. For example, in May 2026, LEHVOSS Nutrition launched ZOΩ3GO Softgels, a finished product concept created by Zooca and Golden Omega. This 1,000 mg softgel is made from 600 mg Golden Omega fish oil concentrates (triglycerides) and 400 mg Calanus oil (wax esters). This formulation also contains SDA, marine policosanols and astaxanthin, along with EPA and DHA.

Growing Use of Microencapsulated Omega-3 Powders

With microencapsulation, manufacturers are able to formulate products such as beverages, enriched foods, nutritional powders, and supplements that can be challenging to formulate using conventional liquid oils. Microencapsulation facilitates the protection of these sensitive fatty acids against oxidation, eliminates marine flavor, and enhances dispersion properties. Following these trends, in May 2026, INNOBIO launched DurOmega Microencapsulated Algae DHA & EPA Powder, which was developed for beverages that require cold-water dispersion and enhanced oxidative stability. This launch addresses the challenges that come with formulating algal oil in liquid formulations.

Major Drivers, Trends, and Challenges

Demand for EPA and DHA ingredients stems from increasing popularity of cardiovascular health, cognitive function, maternal nutrition, and performance nutrition ingredients. However, marine feedstock availability remains an important consideration for manufacturers dependent on fish oil. The 2025 State of The Industry Report - Algal Oil predicted an increase in algal EPA and DHA production, which will amount to 36,000 metric tons in 2030 from 20,000 metric tons in 2025.

On the other hand, companies are facing challenges associated with production cost, oxidative stability, organoleptic properties, and scalability of fermentation-based ingredients. Moreover, microencapsulation needs special control of carrier materials, powder stability, and active fatty acid stability. Thus, companies should be able to combine potent, bioavailable, and scalable ingredients while taking the sourcing issues into account.

For broader ingredient categories, regional analysis, segmentation, and forecasts, consult the full Omega-3 Market Report. This supporting study focuses on specialty lipid sources, EPA and DHA ingredient formats, algal production technologies, concentration methods, and supplier developments.

Table of Contents

1. Global Market Size and Growth Assessment

• Market size, historical trends and forecasts
• Segmentation by omega-3 type, source and format
• Regional market assessment

2. Growth Opportunity Mapping and Where to Play

• High-growth EPA and DHA ingredient categories
• Emerging applications and high-potential geographies
• White spaces in alternative omega-3 sourcing

3. Raw Material Sourcing and Pre-Processing

• Fish species, marine oils and algal feedstocks
• Fisheries, cultivation systems and raw material availability
• Oil extraction, purification and pre-processing

4. Fish Oil-Derived EPA and DHA Production

• EPA-rich and DHA-rich fish oil sources
• Refining, concentration and fatty acid separation
• Purity, oxidation control and quality standardization

5. Algal DHA Production and Ingredient Development

• Microalgae strains and fermentation technologies
• DHA extraction, purification and concentration
• Applications in infant formula and nutritional products

6. Algal EPA and EPA/DHA Production

• EPA-producing microalgae and strain development
• Fermentation optimization and lipid productivity
• Commercial applications of algal EPA ingredients

7. Concentrated Omega-3 Oil Processing

• Molecular distillation and concentration technologies
• Triglyceride and ethyl ester oil formats
• High-potency formulations and ingredient specifications

8. Microencapsulation and Omega-3 Powder Manufacturing

• Spray drying and encapsulation technologies
• Carrier systems, oxidative protection and stability
• Water dispersibility and powder formulation applications

9. Ingredient Formats and Quality Standardization

• Liquid oils, softgels, powders and emulsions
• EPA/DHA concentration and active content verification
• Sensory properties, shelf life and stability testing

10. Application and End-Use Industry Assessment

• Dietary supplements and pharmaceutical nutrition
• Infant formula, maternal and clinical nutrition
• Functional foods, beverages and animal nutrition

11. Global Competitive Landscape and Supplier Benchmarking

• Key fish oil and algal omega-3 manufacturers
• Product portfolios and geographical presence
• Partnerships, product launches and capacity expansions

12. Manufacturing Economics and Cost Assessment

• Fish oil and algal feedstock costs
• Fermentation, concentration and encapsulation expenses
• Production efficiency and supply chain economics

13. Sustainability and Regulatory Landscape

• Responsible fisheries and marine resource management
• Algal cultivation, traceability and environmental assessments
• Food safety, ingredient approvals and quality certifications

14. Emerging Technologies and Product Innovation

• Advanced algal strains and fermentation platforms
• Novel lipid delivery and encapsulation systems
• High-potency ingredients and application-specific formulations

15. Future Outlook and Strategic Opportunities

• Emerging demand for fish-free EPA and DHA ingredients
• Investment opportunities in specialty lipid manufacturing
• Strategic priorities for suppliers and ingredient manufacturers

Related Sources

EPA and DHA Market

Omega-3 Supplements Market

Omega Ingredients Market